Aligos Therapeutics Completes Enrollment in Phase 2 Study of Potential Chronic Hepatitis B Treatment

Phase 2Positive

AI Analysis

Summary

Aligos Therapeutics has completed enrollment in a Phase 2 study of a potential chronic hepatitis B treatment. The completion of enrollment marks progress toward advancing the therapeutic candidate through clinical development.

Clinical Trial Data

Phase

Phase 2

Importance:6/10

Sentiment:

0.50

clinical_trialPhase_2enrollment_completehepatitis_B

Related Companies

$ALGS

Read the original article

Published by yahoo_finance on July 13, 2026 12:33 PM

Read Original